17336-09-3

Upstream product

• 1666-28-0 4-bromosalicylic acid 
• 108-24-7 acetic anhydride 

Downstream Products

• 1403475-75-1 5-bromo-2-(3-phenylpropioloyl)phenyl acetate 
• 1148-47-6 7-bromo-2-phenyl-4H-1-benzopyran-4-one 
• 342422-39-3 C₉H₆BrClO₃ 
• 1175094-51-5 2-(S)-{[4-hydroxy-2-oxo-7-(4-phenoxy-phenyl)-2H-chromene-3-carbonyl]-amino}-propionic acid 
• 1175094-50-4 {[4-hydroxy-2-oxo-7-(4-phenoxy-phenyl)-2H-chromene-3-carbonyl]-amino}-acetic acid 
• 1175095-08-5 4-hydroxy-2-oxo-7-(4-phenoxy-phenyl)-2H-chromene-3-carboxylic acid methyl ester 
• 1262230-72-7 N-[(4-hydroxy-2-oxo-7-phenyl-2H-3-chromenyl)carbonyl]glycine 
• 1262231-09-3 C₂₂H₂₁NO₆ 

Relevant academic research and scientific papers

Demonstrating Ligandability of the LC3A and LC3B Adapter Interface

Autophagy is the common name for a number of lysosome-based degradation pathways of cytosolic cargos. The key components of autophagy are members of Atg8 family proteins involved in almost all steps of the process, from autophagosome formation to their selective fusion with lysosomes. In this study, we show that the homologous members of the human Atg8 family proteins, LC3A and LC3B, are druggable by a small molecule inhibitor novobiocin. Structure-activity relationship (SAR) studies of the 4-hydroxy coumarin core scaffold were performed, supported by a crystal structure of the LC3A dihydronovobiocin complex. The study reports the first nonpeptide inhibitors for these protein interaction targets and will lay the foundation for the development of more potent chemical probes for the Atg8 protein family which may also find applications for the development of autophagy-mediated degraders (AUTACs).

Isoquinolone compound and application thereof

The invention relates to an isoquinolone compound and application thereof. The invention in particular relates to an isoquinolone compound used as a HIF prolyl hydroxylase inhibitor (HIF-PHI) and a pharmaceutical composition thereof. Moreover, the present invention provides the application of the isoquinolinone compound or the pharmaceutical composition thereof in the preparation of a medicament for preventing or treating HIF-associated or HIF-mediated diseases as anemia or ischemia, local ischemia or hypoxia.

COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF

This invention relates to new compounds that can serve as hypoxia mimetics. This invention also relates to methods of increasing HIF levels or activity in a subject or treating a condition associated with HIF levels or activity in a subject by administeri

COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSITIONS, AND USES THEREOF

This invention relates to new compounds that can serve as hypoxia mimetics. This invention also relates to methods of increasing HIF levels or activity in a subject or treating a condition associated with HIF levels or activity in a subject by administeri

CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS

The present invention relates to novel compounds of formula (I), methods, and compositions capable of decreasing HIF hydroxylase activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).